Insider Trading Arrangements

3 Months Ended

Mar. 31, 2026

shares

Trading Arrangements, by Individual

Material Terms of Trading Arrangement

Type of Trading Arrangement
Name and Position	Action	Date	Rule 10b5-1(1)	Non-Rule 10b5-1(2)	Total ADSs to be sold(3)	Expiration Date
Ashley Hall, J.D. Chief Development Officer	Adoption	March 29, 2026	X		Up to 60,432	September 30, 2027
Blai Coll, M.D., Ph.D. Chief Medical Officer	Adoption	March 30, 2026	X		Up to 36,667	September 30, 2027
Xichen Lin, Ph.D. Chief Scientific Officer	Adoption	March 26, 2026	X		Up to 85,144	March 31, 2027

(1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

(2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.

(3) The plan provides for the sale of an aggregate of up to approximately the number of ADSs that have vested or may vest for each officer during the plan period, net of any ADSs the Company withholds to satisfy income tax withholding and remittance obligations in connection with the net settlement of the equity awards, the amount of which cannot currently be determined.

Ashley Hall

Trading Arrangements, by Individual

Name

Ashley Hall

Title

Chief Development Officer

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

March 29, 2026

Expiration Date

September 30, 2027

Aggregate Available

60,432

Blai Coll

Trading Arrangements, by Individual

Name

Blai Coll

Title

Chief Medical Officer

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

March 30, 2026

Expiration Date

September 30, 2027

Aggregate Available

36,667

Xichen Lin

Trading Arrangements, by Individual

Name

Xichen Lin

Title

Chief Scientific Officer

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

March 26, 2026

Expiration Date

March 31, 2027

Aggregate Available

85,144